FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377011318> ?p ?o ?g. }

• W4377011318 endingPage "966" @default.
• W4377011318 startingPage "966" @default.
• W4377011318 abstract "Importance Current third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors for RAS wild-type (WT) MCRC may be valuable for these patients. Objective To compare the anti-EGFR monoclonal antibody panitumumab plus standard-of-care trifluridine-tipiracil with trifluridine-tipiracil alone as third-line therapy for RAS WT MCRC. Design, Setting, and Participants This phase 2 randomized clinical trial (RCT) was conducted in 7 Italian centers from June 2019 to April 2022. Patients with refractory RAS WT MCRC who had a partial or complete response to first-line chemotherapy plus an anti-EGFR monoclonal antibody and an anti-EGFR drug–free interval of 4 or more months during second-line therapy were included. Interventions Patients were randomized 1:1 to receive panitumumab plus trifluridine-tipiracil or trifluridine-tipiracil alone. Main Outcomes and Measures The primary end point was progression-free survival (PFS). Circulating tumor DNA (ctDNA) extended sequence variation analysis was performed in a subgroup of patients. Results Of 62 included patients, 31 received panitumumab plus trifluridine-tipiracil (19 [61.3%] male; median age, 65 years [range, 39-81 years]) and 31 received trifluridine-tipiracil alone (17 [54.8%] male; median age, 66 years [range, 32-82 years]). The primary end point was met. Median PFS was 4.0 months (95% CI, 2.8-5.3 months) in the panitumumab plus trifluridine-tipiracil arm vs 2.5 months (95% CI, 1.4-3.6 months) in the trifluridine-tipiracil only (hazard ratio [HR], 0.48; 95% CI, 0.28-0.82; P = .007). Pretreatment plasma RAS/BRAF WT ctDNA identified patients obtaining prolonged clinical benefit with panitumumab plus trifluridine-tipiracil compared with trifluridine-tipiracil, with PFS rates at 6 months of 38.5% vs 13.0% and at 12 months of 15.4% vs 0%. A ctDNA liquid-biopsy extended mutation analysis by FoundationOne Liquid CDx (profiling 324 genes) was performed in a subgroup of patients with baseline plasma RAS/BRAF WT ctDNA; in 15 of 23 patients (65.2%) whose tumors were WT for KRAS , NRAS , BRAFV600E , EGFR , ERBB2 , MAP2K1 , and PIK3CA , median PFS was 6.4 months (95% CI, 3.7-9.2 months). Within this group of 15 patients, 2 (13.3%) had partial response, 11 (73.3%) had stable disease, and 2 (13.3%) had disease progression as best response. Conclusions and Relevance In this RCT, third-line treatment with the anti-EGFR monoclonal antibody panitumumab plus the standard-of-care trifluridine-tipiracil resulted in improved PFS compared with treatment with trifluridine-tipiracil alone among patients with refractory RAS WT MCRC. The findings support the clinical utility of liquid biopsy–guided anti-EGFR rechallenge therapy for refractory RAS WT MCRC. Trial Registration ClinicalTrials.gov Identifier: NCT05468892" @default.
• W4377011318 created "2023-05-19" @default.
• W4377011318 creator A5001896992 @default.
• W4377011318 creator A5002124283 @default.
• W4377011318 creator A5004016643 @default.
• W4377011318 creator A5006208754 @default.
• W4377011318 creator A5007575010 @default.
• W4377011318 creator A5008135397 @default.
• W4377011318 creator A5008674075 @default.
• W4377011318 creator A5009130863 @default.
• W4377011318 creator A5011947444 @default.
• W4377011318 creator A5020655022 @default.
• W4377011318 creator A5025152244 @default.
• W4377011318 creator A5032164411 @default.
• W4377011318 creator A5037047992 @default.
• W4377011318 creator A5038665049 @default.
• W4377011318 creator A5039682482 @default.
• W4377011318 creator A5043177546 @default.
• W4377011318 creator A5062813302 @default.
• W4377011318 creator A5072080597 @default.
• W4377011318 creator A5076690603 @default.
• W4377011318 creator A5083277135 @default.
• W4377011318 creator A5085124809 @default.
• W4377011318 creator A5088304855 @default.
• W4377011318 creator A5091765229 @default.
• W4377011318 date "2023-07-01" @default.
• W4377011318 modified "2023-10-14" @default.
• W4377011318 title "Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory <i>RAS</i> Wild-Type Metastatic Colorectal Cancer" @default.
• W4377011318 cites W2901178367 @default.
• W4377011318 cites W2901367407 @default.
• W4377011318 cites W2955389905 @default.
• W4377011318 cites W2979386314 @default.
• W4377011318 cites W2987148655 @default.
• W4377011318 cites W2999771324 @default.
• W4377011318 cites W3153189337 @default.
• W4377011318 cites W3153990830 @default.
• W4377011318 cites W3182019035 @default.
• W4377011318 cites W3191292273 @default.
• W4377011318 cites W4283587297 @default.
• W4377011318 cites W4284703432 @default.
• W4377011318 cites W4285249625 @default.
• W4377011318 cites W4289261231 @default.
• W4377011318 cites W4307401860 @default.
• W4377011318 doi "https://doi.org/10.1001/jamaoncol.2023.0655" @default.
• W4377011318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37200022" @default.
• W4377011318 hasPublicationYear "2023" @default.
• W4377011318 type Work @default.
• W4377011318 citedByCount "1" @default.
• W4377011318 countsByYear W43770113182023 @default.
• W4377011318 crossrefType "journal-article" @default.
• W4377011318 hasAuthorship W4377011318A5001896992 @default.
• W4377011318 hasAuthorship W4377011318A5002124283 @default.
• W4377011318 hasAuthorship W4377011318A5004016643 @default.
• W4377011318 hasAuthorship W4377011318A5006208754 @default.
• W4377011318 hasAuthorship W4377011318A5007575010 @default.
• W4377011318 hasAuthorship W4377011318A5008135397 @default.
• W4377011318 hasAuthorship W4377011318A5008674075 @default.
• W4377011318 hasAuthorship W4377011318A5009130863 @default.
• W4377011318 hasAuthorship W4377011318A5011947444 @default.
• W4377011318 hasAuthorship W4377011318A5020655022 @default.
• W4377011318 hasAuthorship W4377011318A5025152244 @default.
• W4377011318 hasAuthorship W4377011318A5032164411 @default.
• W4377011318 hasAuthorship W4377011318A5037047992 @default.
• W4377011318 hasAuthorship W4377011318A5038665049 @default.
• W4377011318 hasAuthorship W4377011318A5039682482 @default.
• W4377011318 hasAuthorship W4377011318A5043177546 @default.
• W4377011318 hasAuthorship W4377011318A5062813302 @default.
• W4377011318 hasAuthorship W4377011318A5072080597 @default.
• W4377011318 hasAuthorship W4377011318A5076690603 @default.
• W4377011318 hasAuthorship W4377011318A5083277135 @default.
• W4377011318 hasAuthorship W4377011318A5085124809 @default.
• W4377011318 hasAuthorship W4377011318A5088304855 @default.
• W4377011318 hasAuthorship W4377011318A5091765229 @default.
• W4377011318 hasBestOaLocation W43770113181 @default.
• W4377011318 hasConcept C121608353 @default.
• W4377011318 hasConcept C126322002 @default.
• W4377011318 hasConcept C143998085 @default.
• W4377011318 hasConcept C203092338 @default.
• W4377011318 hasConcept C207103383 @default.
• W4377011318 hasConcept C2776694085 @default.
• W4377011318 hasConcept C2778332735 @default.
• W4377011318 hasConcept C2779438470 @default.
• W4377011318 hasConcept C2779998722 @default.
• W4377011318 hasConcept C44249647 @default.
• W4377011318 hasConcept C526805850 @default.
• W4377011318 hasConcept C535046627 @default.
• W4377011318 hasConcept C71924100 @default.
• W4377011318 hasConcept C90924648 @default.
• W4377011318 hasConceptScore W4377011318C121608353 @default.
• W4377011318 hasConceptScore W4377011318C126322002 @default.
• W4377011318 hasConceptScore W4377011318C143998085 @default.
• W4377011318 hasConceptScore W4377011318C203092338 @default.
• W4377011318 hasConceptScore W4377011318C207103383 @default.
• W4377011318 hasConceptScore W4377011318C2776694085 @default.
• W4377011318 hasConceptScore W4377011318C2778332735 @default.
• W4377011318 hasConceptScore W4377011318C2779438470 @default.
• W4377011318 hasConceptScore W4377011318C2779998722 @default.
• W4377011318 hasConceptScore W4377011318C44249647 @default.

• next